JP7065081B2 - Ｇｐｒ１２０モジュレーターとして有用な二環式化合物 - Google Patents

Ｇｐｒ１２０モジュレーターとして有用な二環式化合物 Download PDF

Info

Publication number
JP7065081B2
JP7065081B2 JP2019513944A JP2019513944A JP7065081B2 JP 7065081 B2 JP7065081 B2 JP 7065081B2 JP 2019513944 A JP2019513944 A JP 2019513944A JP 2019513944 A JP2019513944 A JP 2019513944A JP 7065081 B2 JP7065081 B2 JP 7065081B2
Authority
JP
Japan
Prior art keywords
compound
optionally substituted
composition
mammal
mmol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019513944A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019533642A (ja
JP2019533642A5 (enExample
Inventor
ブライアン ライムンド，
エレナ エス． コルタン，
ジョン グリフィン，
エリック ステインジェランド，
Original Assignee
インテグラル ヘルス， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by インテグラル ヘルス， インコーポレイテッド filed Critical インテグラル ヘルス， インコーポレイテッド
Publication of JP2019533642A publication Critical patent/JP2019533642A/ja
Publication of JP2019533642A5 publication Critical patent/JP2019533642A5/ja
Application granted granted Critical
Publication of JP7065081B2 publication Critical patent/JP7065081B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D275/00—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
    • C07D275/04—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D275/06—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings condensed with carbocyclic rings or ring systems with hetero atoms directly attached to the ring sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2019513944A 2016-09-12 2017-09-11 Ｇｐｒ１２０モジュレーターとして有用な二環式化合物 Active JP7065081B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662393619P 2016-09-12 2016-09-12
US62/393,619 2016-09-12
PCT/US2017/050964 WO2018049328A1 (en) 2016-09-12 2017-09-11 Bicyclic compounds useful as gpr120 modulators

Publications (3)

Publication Number Publication Date
JP2019533642A JP2019533642A (ja) 2019-11-21
JP2019533642A5 JP2019533642A5 (enExample) 2020-11-12
JP7065081B2 true JP7065081B2 (ja) 2022-05-11

Family

ID=61562078

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019513944A Active JP7065081B2 (ja) 2016-09-12 2017-09-11 Ｇｐｒ１２０モジュレーターとして有用な二環式化合物

Country Status (7)

Country Link
US (2) US10865201B2 (enExample)
EP (1) EP3509588B1 (enExample)
JP (1) JP7065081B2 (enExample)
KR (1) KR102539877B1 (enExample)
CN (1) CN110121343B (enExample)
CA (1) CA3041038A1 (enExample)
WO (1) WO2018049328A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7086942B2 (ja) 2016-09-12 2022-06-20 インテグラル ヘルス， インコーポレイテッド Ｇｐｒ１２０モジュレーターとして有用な単環式化合物
CA3041038A1 (en) * 2016-09-12 2018-03-15 Numerate, Inc. Bicyclic compounds useful as gpr120 modulators
AU2019255363A1 (en) * 2018-04-20 2020-11-05 Krish Biotech Research Private Limited Method of treatment of non-alcoholic steatohepatitis, nash
CN111499592B (zh) * 2020-03-14 2023-06-23 江苏省农用激素工程技术研究中心有限公司 5-氨甲基糖精的合成方法
CN111574414A (zh) * 2020-05-20 2020-08-25 上海毕得医药科技有限公司 一种4-溴-2-甲氧基苯磺酰氯的合成方法
CN114671827B (zh) * 2020-12-24 2024-09-20 杭州百新生物医药科技有限公司 邻苯甲酰磺酰亚胺类衍生物及其应用
CN114685395A (zh) * 2020-12-29 2022-07-01 浙江大学 一种2,3-二氢苯并[d]异噻唑类化合物及其应用
WO2024046323A1 (zh) * 2022-08-29 2024-03-07 山东大学 一种苯并五元氮环类化合物、其制备方法及医药用途
CN116730945B (zh) * 2023-08-10 2023-11-17 北京惠宇乐邦环保科技有限公司 糖精的制备方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004523590A (ja) 2001-03-22 2004-08-05 ベーリンガー インゲルハイム （カナダ） リミテッド 非ヌクレオシド逆転写酵素阻害剤

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2735225A (en) 1956-02-21 Table ix p petri dish tests with x-phthalimido-
DE2253251A1 (de) 1972-10-30 1974-05-09 Thomae Gmbh Dr K Neue phthalimido-sulfonylharnstoffe
EP0145078B1 (en) * 1983-12-02 1988-10-12 Shell Internationale Researchmaatschappij B.V. Diphenyl ether herbicides
FR2659327A1 (fr) 1990-03-08 1991-09-13 Centre Nat Rech Scient Derives du benzisothiazolinone-1-dioxyde, utilisables comme inhibiteurs des elastases.
ATE162525T1 (de) 1991-07-30 1998-02-15 Ciba Geigy Ag Heteroaryl substituierte hydroxylaminderivate als lipoxygenase-inhibitoren
US5350761A (en) * 1991-07-30 1994-09-27 Ciba-Geigy Corporation Indolyl substituted hydroxylamine derivatives
US5334600A (en) * 1991-07-30 1994-08-02 Ciba-Geigy Corporation Isoquinolyl substituted hydroxylamine derivatives
TW219935B (enExample) * 1991-12-25 1994-02-01 Mitsubishi Chemicals Co Ltd
US5599811A (en) * 1995-02-21 1997-02-04 Warner-Lambert Company Benzothiazine dioxides as endothelin antagonists
EP0891332B1 (en) 1996-03-29 2004-03-17 Pfizer Inc. 6-phenylpyridyl-2-amine derivatives
GB0124627D0 (en) * 2001-10-15 2001-12-05 Smithkline Beecham Plc Novel compounds
DE10348022A1 (de) 2003-10-15 2005-05-25 Imtm Gmbh Neue Dipeptidylpeptidase IV-Inhibitoren zur funktionellen Beeinflussung unterschiedlicher Zellen und zur Behandlung immunologischer, entzündlicher, neuronaler und anderer Erkrankungen
TW200613272A (en) 2004-08-13 2006-05-01 Astrazeneca Ab Isoindolone compounds and their use as metabotropic glutamate receptor potentiators
WO2006038594A1 (ja) * 2004-10-04 2006-04-13 Ono Pharmaceutical Co., Ltd. Ｎ型カルシウムチャネル阻害薬
US8110681B2 (en) 2006-03-17 2012-02-07 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Compounds for the treatment of spinal muscular atrophy and other uses
NZ577981A (en) * 2006-12-27 2011-12-22 Sanofi Aventis Substituted isoquinoline and isoquinolinone derivatives as inhibitors of rho-kinase
AU2008218951B2 (en) * 2007-02-22 2011-11-17 Irm Llc Compounds and methods for modulating g protein-coupled receptors
US8569378B2 (en) 2007-07-20 2013-10-29 Toshiyuki Sakai p27 protein inducer
CA2740366A1 (en) 2008-10-21 2010-04-29 Metabolex, Inc. Aryl gpr120 receptor agonists and uses thereof
AR074760A1 (es) 2008-12-18 2011-02-09 Metabolex Inc Agonistas del receptor gpr120 y usos de los mismos en medicamentos para el tratamiento de diabetes y el sindrome metabolico.
US8362052B2 (en) * 2009-03-11 2013-01-29 Msd K.K. Isoindolin-1-one derivative
US8314120B2 (en) 2010-03-30 2012-11-20 Abbott Gmbh & Co. Kg Small molecule potentiators of metabotropic glutamate receptors
US8299117B2 (en) 2010-06-16 2012-10-30 Metabolex Inc. GPR120 receptor agonists and uses thereof
CA2801182A1 (en) 2010-06-16 2011-12-22 Metabolex, Inc. Gpr120 receptor agonists and uses thereof
TW201200505A (en) * 2010-06-17 2012-01-01 Metabolex Inc GPR120 receptor agonists and uses thereof
EP2731944A1 (en) 2011-07-15 2014-05-21 Pfizer Inc Gpr 119 modulators
EA035454B1 (ru) 2011-11-30 2020-06-18 Ф.Хоффманн-Ля Рош Аг Бициклические производные дигидроизохинолин-1-она
RU2015116540A (ru) 2012-10-11 2016-12-10 Мерк Шарп И Доум Корп. Замещенные соединения спиропиперидинила, применяемые в качестве агонистов gpr120
KR101942752B1 (ko) * 2012-11-05 2019-01-28 주식회사 엘지화학 Ｇｐｒ120 효능제로서의 티오아릴 유도체
CA2893239A1 (en) 2012-12-03 2014-06-12 F. Hoffmann-La Roche Ag Substituted triazole and imidazole compounds
US9714252B2 (en) 2012-12-20 2017-07-25 Purdue Pharma L.P. Cyclic sulfonamides as sodium channel blockers
WO2014159061A2 (en) * 2013-03-14 2014-10-02 Janssen Pharmaceutica Nv Benzo-fused heterocyclic derivatives useful as agonists of gpr120
AU2014237600B2 (en) * 2013-03-14 2018-03-22 Janssen Pharmaceutica Nv Bicyclic pyrrole derivatives useful as agonists of GPR120
DK3013796T3 (da) 2013-06-27 2020-03-16 Lg Chemical Ltd Biarylderivater som gpr120-agonister
AR099937A1 (es) 2014-04-04 2016-08-31 Sanofi Sa Compuestos de isoindolinona como moduladores de gpr119 para el tratamiento de diabetes, obesidad, dislipidemia y trastornos relacionados
BR112016024936A2 (pt) 2014-05-07 2017-08-15 Bristol Myers Squibb Co moduladores de gpr40 à base de pirrolidina para tratamento de doenças como diabetes
CN107074817B (zh) * 2014-08-29 2023-12-15 Chdi基金会股份有限公司 用于成像亨廷顿蛋白的探针
JP6486699B2 (ja) 2015-01-29 2019-03-20 国立大学法人金沢大学 脱水縮合剤
US10457669B2 (en) * 2015-10-21 2019-10-29 Otsuka Pharmaceutical Co., Ltd. Benzolactam compounds as protein kinase inhibitors
CA3041038A1 (en) * 2016-09-12 2018-03-15 Numerate, Inc. Bicyclic compounds useful as gpr120 modulators
JP7086942B2 (ja) * 2016-09-12 2022-06-20 インテグラル ヘルス， インコーポレイテッド Ｇｐｒ１２０モジュレーターとして有用な単環式化合物

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004523590A (ja) 2001-03-22 2004-08-05 ベーリンガー インゲルハイム （カナダ） リミテッド 非ヌクレオシド逆転写酵素阻害剤

Also Published As

Publication number Publication date
JP2019533642A (ja) 2019-11-21
KR20190068535A (ko) 2019-06-18
US10865201B2 (en) 2020-12-15
EP3509588C0 (en) 2023-06-07
CN110121343B (zh) 2023-11-03
US20190218208A1 (en) 2019-07-18
EP3509588A4 (en) 2020-04-29
US20210347768A1 (en) 2021-11-11
EP3509588B1 (en) 2023-06-07
CN110121343A (zh) 2019-08-13
EP3509588A1 (en) 2019-07-17
CA3041038A1 (en) 2018-03-15
US11919891B2 (en) 2024-03-05
KR102539877B1 (ko) 2023-06-05
WO2018049328A1 (en) 2018-03-15

Similar Documents

Publication Publication Date Title
JP7065081B2 (ja) Ｇｐｒ１２０モジュレーターとして有用な二環式化合物
JP7086942B2 (ja) Ｇｐｒ１２０モジュレーターとして有用な単環式化合物
JP7637281B2 (ja) ラニフィブラノールの重水素化誘導体
US8940769B2 (en) Biaryl benzoimidazole derivatives and pharmaceutical composition comprising the same
KR102240158B1 (ko) 사이클로알킬산 유도체, 그의 제조 방법, 및 그의 약학적 용도
CN1129102A (zh) 用作肿瘤坏死因子释放抑制剂的儿茶酚二醚化合物
JP2016511237A (ja) 選択的ｈｄａｃ３阻害剤
JP2019077713A (ja) ＮＲ２ＢのＮ−アルキルアリール−５−オキシアリール−オクタヒドロ−シクロペンタ［ｃ］ピロールネガティブアロステリックモジュレーター
JP2009533410A (ja) Ｇタンパク質共役型受容体（ｇｐｒ１１９）アゴニストとしてのアゼチジン誘導体
JPH0236163A (ja) 新規なヒドロキサメート誘導体
US20090176837A1 (en) Compounds with activity at retinoic acid receptors
KR20210082466A (ko) 샤페론-매개 자가포식작용 조절제로서 유용한 벤족사졸 및 관련된 화합물
WO2002020462A1 (en) Benzoic acid derivatives and drugs containing the same as the active ingredient
US8575210B2 (en) Use of indole derivatives as NURR-1 activators for treating parkinson's disease
CN116438174A (zh) 化合物及其作为mif抑制剂的用途
HK40005335A (en) Bicyclic compounds useful as gpr120 modulators
HK40005335B (en) Bicyclic compounds useful as gpr120 modulators
HK40005332B (en) Monocyclic compounds useful as gpr120 modulators
HK40005332A (en) Monocyclic compounds useful as gpr120 modulators

Legal Events

Date Code Title Description
A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20200902

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200910

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200910

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20210729

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210816

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211116

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220331

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220425

R150 Certificate of patent or registration of utility model

Ref document number: 7065081

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250